Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Flagstar Bank NA (FLG) Price & Performance

ADMA Biologics IncTrade
Flagstar Bank NATrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Flagstar Bank NA — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Flagstar Bank NA trades at $14.23 (market cap $5.82B). The key difference: Flagstar Bank NA is far larger — about 2.7× ADMA Biologics Inc's market cap, and Flagstar Bank NA pays a 0.29% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAFLG
Market Cap
$2.18B$5.82B
Sector
HealthFinancials
52-Week High
$20.38$15.36
52-Week Low
$7.60$10.72
Enterprise Value
$2.25B
Dividend Yield
0.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Flagstar Bank NA

Flagstar Bank (FLG) trades at $13.95, down 1.48% amid a bearish technical signal, though it remains profitable with a net income margin of 2.3% in 2026. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and continues dividend payments, reflecting confidence in its capital position. The stock trades below book value with a P/B of 0.76, offering a potential margin of safety.

The outlook is mixed: analyst consensus is bullish with a $16.85 price target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of growth initiatives, while downside could stem from further earnings misses or economic headwinds affecting the banking sector.

Returns comparison

Trailing returns across standard periods

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG